Biogen boosts MS drug portfolio | December 4, 2017 Issue - Vol. 95 Issue 48 | Chemical & Engineering News
Volume 95 Issue 48 | p. 15 | Concentrates
Issue Date: December 4, 2017

Biogen boosts MS drug portfolio

By Ryan Cross
Department: Business
Keywords: Neuroscience, multiple sclerosis, Biogen, Alkermes

Biogen will take over development of an Alkermes small-molecule drug for multiple sclerosis (MS). The compound, ALKS 8700, is in Phase III clinical trials and would compete with Biogen’s MS drug Tecfidera. ALKS 8700, based on monomethyl fumarate, is anticipated to have fewer gastro­intestinal side effects than Tecfidera, which is based on dimethyl fumarate. Alkermes will get an up-front payment of $28 million and could earn $200 million in milestones, plus royalties.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment